World of DTC Marketing

SEPTEMBER 17, 2020

In 2019, 12 states had obesity rates in the highest category for this survey (35 percent or greater), a jump from three states in 2014, and nine in 2018. If that doesn’t work then patients who are obese need to pay more for health insurance, plain and simple. We need to do to obesity what we did for smoking.

Healthcare 242

Healthcare Healthcare Insurance Healthcare Provider 242

Pharmaceutical Commerce

JANUARY 15, 2024

FDA approves Keytruda (pembrolizumab) combined with chemoradiation for the treatment of patients with FIGO 2014 stage III to IVA cervical cancer, which is the 39th overall approved indication for the drug in the United States.

FDA 108

FDA Patients 108

Evolve Your Success

MAY 10, 2022

In a world of medical and health jargon, it can be difficult for patients to understand the kind of care they are getting. Sometimes, beyond the language, it is in the way health professionals communicate to the patient and their families as well as to each other. They are also patient advocates from their experience in nursing.

Education 130

Education Patients Medical sales reps Medical sales 130

PM360

AUGUST 29, 2022

Recently, industry and community patient advocacy pioneers came together for the Chief Patient Officer Summit. Though the title is rare, having a leader highly placed within a biopharmaceutical company solely responsible for integrating patient perspectives is no longer Pollyanna. That was 2014. Succeeding Internally.

Patients 98

Patients Ethics Insurance Recruitment 98

World of DTC Marketing

MAY 26, 2021

Today, Imbruvica is priced at $181,529 per year for a patient taking three pills per day, compared to $99,776 per year at launch. For a patient taking 3 tablets daily, the annual net price of Imbruvica increased from $72,587 in 2013 to $115,533 in 2017 (the last year for which AbbVie provided the Committee data). AbbVie’s yearly U.S.

Competition 180

Competition Marketing Government Patients 180

World of DTC Marketing

SEPTEMBER 7, 2022

While that sounds encouraging, most cancer drugs launched between 2009 and 2014 cost more than USD 100,000 annually. For DTC, the model will become one of collaboration with patients as they help them navigate the complex system of American healthcare. Their future model includes helping HCPs rather than trying to sell to them.

Pharma 210

Pharma Food and Drug Administration Marketing Prescription 210

Pharmacy Times

JANUARY 16, 2024

Previously, IgG-hyaluronidase recombinant was approved by the FDA in 2014 for the treatment of primary immunodeficiency in adult patients and has expanded to include some pediatric patients.

FDA 58

FDA Patients 58

Legacy MEDSearch

JUNE 15, 2023

“At Cala, we’ve always been committed to expanding patient access and accelerating innovation in TAPS therapy for indications beyond essential tremor,” said Renee Ryan, CEO at Cala. “By By expanding into Parkinson’s disease, we are now able to bring this powerful treatment to additional patients who suffer from action hand tremors.”

Patients 98

Patients Recruitment Management Pharmacology 98

pharmaphorum

NOVEMBER 29, 2022

At NeoImmuneTech, a Biotech company founded in Maryland, US, in 2014, the answer to this question looks straightforward: “We believe in incremental progress”, says Dr Se Hwan Yang, president and chief executive officer of the company. It is worth noting that patients with r/r PaC or r/r MSS-CRC have very limited treatment options.

Safety 106

Safety Patients Engineering Recruitment 106

Pharmaceutical Technology

JANUARY 22, 2023

Eli Lilly and Company and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets for chronic kidney disease (CKD) in adult patients.

Food and Drug Administration 105

Food and Drug Administration FDA Food Patients 105

Pharmacy Times

NOVEMBER 11, 2022

Updated prescribing guidelines issued in 2014 and 2016 may explain lower use of opioids by 11.7% among patients with chronic, nonsurgical pain.

Patients 49

Patients 49

pharmaphorum

NOVEMBER 2, 2022

With the merger now completed, Norstella becomes a $5 billion group with 1,500 employees across the five business brands with the overarching objective of guiding life sciences companies through the drug development process so patients can get access to therapies more quickly. Photo by Edge2Edge Media on Unsplash.

Pharma 101

Pharma Marketing Patients Consulting 101

pharmaphorum

AUGUST 16, 2022

Lynparza was approved in 2020 as a second-line therapy for homologous recombination repair (HRR) gene-mutated mCRPC last year, but extending its label to include non-HRR patients in the frontline setting would dramatically increase the number of patients eligible for treatment. billion in the first half of this year.

FDA 111

FDA Patients Sales Marketing 111

European Pharmaceutical Review

NOVEMBER 2, 2022

The advanced facility will be based on the Regenerative Medicine Clinic established at Cedars-Sinai in 2014, developing clinical trials for neurological, cardiovascular, musculoskeletal and autoimmune diseases. The Cedars-Sinai Board of Governors Regenerative Medicine Institute and the Smidt Heart Institute will lead the project.

Food and Drug Administration 98

Food and Drug Administration Medicine Training Electronics 98

European Pharmaceutical Review

APRIL 29, 2024

This means that patients with the rare genetic bleeding disorder can produce FIX themselves instead of relying on regular intravenous infusions of FIX, which is the current standard of care, according to 2015 research highlighted by Pfizer. Pfizer licensed BEQVEZ from Spark Therapeutics in December 2014.

Food and Drug Administration 96

Food and Drug Administration Medicine FDA Food 96

pharmaphorum

OCTOBER 3, 2022

After review of all data, including RWE, feedback from patients and clinicians and caregivers, as well as that collected from the MAA – NICE released its draft guidance based on “limited and highly uncertain” evidence of improved later stages of the disease or improved survival with Translarna.

Patients 98

Patients Medicine FDA Management 98

World of DTC Marketing

AUGUST 31, 2022

” According to a 2014 study by the Intramural Research Program — a subsidiary of the National Institutes of Health—extreme obesity may shorten life expectancy by up to 14 years. . “Obesity rates among older Americans nearly doubled between 1988 and 2018, increasing from 22% to 40%.

Food 176

Food Government Leads Patients 176

pharmaphorum

OCTOBER 26, 2022

The first patient has already been enrolled into its FIBRONEER phase 3 programme for BI 1015550, which already has a breakthrough designation from the FDA after a positive phase 2 trial showed improved lung function in patients with IPF over a 12-week period. There are more than 200 lung disorders that can lead to pulmonary fibrosis.

Recruitment 98

Recruitment Prospecting Marketing Patients 98

European Pharmaceutical Review

SEPTEMBER 20, 2023

Since 2014, he has worked in biopharmaceutical analysis, focusing on the design and implementation of different analytical strategies for analysis of therapeutic proteins, mAbs and ADCs using mass spectrometry. The post The benefits of mass spectrometry for expediting biologics to patients appeared first on European Pharmaceutical Review.

Patients 98

Patients Manufacturing Leads Safety 98

PharmExec

JANUARY 15, 2024

The FDA issued the 39th overall approval for Keytruda (pembrolizumab), with the latest in combination with chemoradiation for the treatment of patients with FIGO 2014 stage III to IVA cervical cancer.

FDA 52

FDA Patients 52

Pharmaceutical Technology

MAY 16, 2023

Silverthorn said to Pharmaceutical Technology , the consortium aims to overcome the current patient participation in clinical trial barriers, associated with rare diseases , by working with patient advocacy groups and contact registries. The BGTC was launched in October 2021, as the first AMP initiative.

Manufacturing 90

Manufacturing Patients Medicine FDA 90

pharmaphorum

DECEMBER 14, 2022

When patients experience intense emotion, either positive or negative, they are rendered unconscious. In order to bring it to market, a special program called Risk Evaluation and Mitigation Strategy (REMS) had to be put in place, where only eligible patients could access the drug through a very strict process. One more hurdle to clear.

Competition 117

Competition FDA Pharmaceutical Marketing 117

PM360

SEPTEMBER 30, 2024

Practices HCPs should follow to ensure patient confidence and success. The need for patient centricity is ubiquitous, yet the patient journey is still daunting for most and impossible for some. Many patients fail to reach an accurate diagnosis for their condition, or if diagnosed, fail to adhere to their prescribed treatment.

Patients 52

Patients Education Insurance Physicians 52

Pharmaceutical Technology

APRIL 3, 2023

According to GlobalData’s Clinical Trials Database, gene therapy trials represent a 0.91% share of all planned trials in 2023, up from just 0.25% in 2014. GlobalData, the parent company of Pharmaceutical Technology, outlines a rise in gene therapy trials in 2023, in line with the growing market Fáber describes.

Media 98

Media Pharmaceutical Marketing Manufacturing 98

pharmaphorum

OCTOBER 5, 2022

The consequences of this – for individual patients, healthcare systems, innovation, and the wider R&D community – are as obvious as they are far reaching, she goes on. This access conundrum was acknowledged by NICE as far back as 2014, and has been sitting in pharma’s “inbox” for some time. Too hard to fix? Growing momentum.

Medicine 98

Medicine Competition Patients Marketing 98

Medico Reach

AUGUST 18, 2022

Now, besides maintaining patient records and facilitating seamless test procedures, the organization also: Assists pharmaceutical and biotech companies in drug development Guides patients in finding optimal cancer therapy solutions Helps medical professionals make informed decisions through clinical studies. Flatiron Health.

Healthcare 98

Healthcare Healthcare Medical Doctors 98

pharmaphorum

OCTOBER 24, 2022

It’s not just good for the company: for patients, these can be treatments that can make all the difference to them. The PPRS changed over time, and the 2014 PPRS first introduced a cap to NHS branded medicines spending delivered via rebates. As ever, the controversy is about the trade-offs and just where to draw the line.

Medicine 75

Medicine Sales Specialization Marketing 75

European Pharmaceutical Review

JANUARY 30, 2025

He joined Takeda as CEO in April 2014. She is an experienced, values-based leader who will fully uphold our corporate culture and expand the impact we can have for patients around the world, remarked Masami Iijima, chair of the Board of Directors meeting and of the Nomination Committee.

Competition 59

Competition Marketing Management Leads 59

European Pharmaceutical Review

JULY 26, 2024

This new regulatory approval by the European Commission is indicated for patients without a history of factor IX inhibitors and without detectable antibodies to variant AAV serotype Rh74. The pharmaceutical company licensed the gene therapy DURVEQTIX from Spark ® Therapeutics in December 2014.

Food and Drug Administration 52

Food and Drug Administration Engineering Food Patients 52

European Pharmaceutical Review

AUGUST 23, 2022

FAKE MEDICINES are not a new problem, and pose a tremendous threat to patient safety and public health in society regardless of a country’s economic status. Unfortunately, such a chain of custody is not intended to provide patients with the ability to verify their own medicines. Available from: [link]. Leem JW, Jeon HJ, Ji Y, et al.

Medicine 98

Medicine Food and Drug Administration Pharmaceutical products Pharmaceutical 98

European Pharmaceutical Review

JANUARY 18, 2024

The company predicted this will be “driven by an increase in the patient share of dual orexin receptor antagonists (DORAs)”. Although the research noted that younger patients are increasingly switching from ERT to SRT, the current “familiarity” of existing therapies are expected to play a part in impeding the market’s expansion.

Marketing 98

Marketing Sales Pharmacology Pharma 98

pharmaphorum

JANUARY 3, 2023

After passing on the reins of NICE, he was appointed chair of the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), heading up the agency for two 3-year terms between 2014 and 2020.

Medicine 52

Medicine Side effects Safety Healthcare 52

pharmaphorum

NOVEMBER 16, 2022

This first FDA antibody-drug conjugate (ADC)-approval for platinum-resistant ovarian cancer indication covers those patients who have undergone one to three prior systemic treatment regimens, regardless of prior Avastin use. The drug’s safety has been evaluated from a pooled analysis of three studies among a total of 464 patients with (FR?)-positive,

FDA 69

FDA Patients Safety Medicine 69

pharmaphorum

AUGUST 4, 2022

It was supposed to enrol 200 subjects and generate results in 2014. Patients in REALM-DCM will now stop study medication and complete any necessary follow-up evaluations, under the guidance of study site investigators. of DCM patients had LMNA mutations. One study found that around 7.5%

Biopharma 65

Biopharma Leads Patients Medical 65

Pharma Leaders

JUNE 27, 2023

Intended to treat adult patients, fidanacogene elaparvovec is an investigational therapy that comprises a bio-engineered adeno-associated virus (AAV) capsid and a human coagulation Factor IX (FIX) gene variant. Pfizer obtained the licence for gene therapy from Spark Therapeutics in December 2014.

Food and Drug Administration 52

Food and Drug Administration FDA Safety Engineering 52

Pharmaceutical Technology

JANUARY 23, 2023

However, this progress is not reflected with respect to approved treatments for paediatric IBD patients. Therefore, with an inadequate or loss of response to these anti-TNFs, clinicians must prescribe adult therapies off-label to treat younger patients.

Medical 59

Medical Ethics Specialization Physicians 59

pharmaphorum

JANUARY 9, 2023

It also has potential in NDD, although it was discontinued as a treatment of fragile X syndrome in 2014 after disappointing phase 2b trial results. The market potential of the CUD and NDD indications alone could top 2 billion euros ($2.12 billion) globally, the company noted. Lynn Durham.

Pharma 59

Pharma Patients Medical Marketing 59